Investigation of gut microbiota metabolite-mediated transkingdom interactions with fungi
Project Number1R01AI178683-01A1
Former Number1R01AI178683-01A1
Contact PI/Project LeaderILIEV, ILIYAN DIMITROV Other PIs
Awardee OrganizationWEILL MEDICAL COLL OF CORNELL UNIV
Description
Abstract Text
Project Summary
The human intestinal tract supports a complex microbial environment consisting of bacterial (or
microbiota) and fungal (or mycobiota) constituents. Although the role of each of these communities has been a
subject of multiple studies, the role of transkingdom interactions between fungi and bacteria in shaping host
immunity and physiology has been much less explored. The chemical basis for such interactions, critical for the
rational design of mechanistic studies with regards to host immunity and disease development, remain
completely uncharted territory in the literature. We have established a genetic manipulation pipeline to identify
gene transfer methodology and build a genetic tool for nonmodel human gut bacteria on a large scale. Via a
multifactorial optimization of their conjugation/transformation conditions and targeting bacterial conserved 16s
rRNA genes, this pipeline efficiently identified the gene transfer methods for multiple nonmodel gut bacterial
commensals and set up CRISPR-based or gene insertion tools in multiple of them. This library of genetically
targetable microbes comes from 5 different phyla. This genetic manipulation pipeline and this library of tractable
commensals will facilitate our investigation of trans-kingdom microbiota-mycobiota interactions at the molecular
level. A high throughput screening of bacterial metabolite libraries from gut bacteria identified metabolites with
direct effect on intestinal mycobiota. We identified bacterial species and corresponding gene clusters responsible
for the production of these metabolites. Our preliminary data suggest strong ties and specific molecular
interactions between fungi and bacteria in the gut that have previously unappreciated role in microbial dynamics,
metabolite production and immunity. We will utilize such bacterial strains and isogenic mutants in key
biosynthetic pathways to target metabolites with mycobiota modulatory properties. We will use several mouse
models and synthetic microbial communities to define the role of trans kingdom interaction between bacteria and
fungi in modulating host immunity and colonization resistance in the gut. We hypothesize that metabolites from
the human bacterial microbiota modulate the fungal communities in the gut to affect microbial composition, the
microbiome function and immunity. In addition to revealing novel mechanisms of fungal-bacterial interaction at
an unprecedented small molecule level, the results of this proposed investigation will illuminate potential new
strategies for targeting of fungal pathogens
Public Health Relevance Statement
Project Narrative
The human intestinal flora is a complex environment where bacterial and fungal organisms co-exist in the gut.
While the microbiome can profoundly influence host physiology, specific fungal-bacterial transkingdom
interactions remain poorly characterized. The proposed research will analyze interactions between these
organisms and their specific influence on immunity and mycobiota.
National Institute of Allergy and Infectious Diseases
CFDA Code
855
DUNS Number
060217502
UEI
YNT8TCJH8FQ8
Project Start Date
01-March-2024
Project End Date
31-January-2029
Budget Start Date
01-March-2024
Budget End Date
31-January-2025
Project Funding Information for 2024
Total Funding
$828,994
Direct Costs
$489,082
Indirect Costs
$339,912
Year
Funding IC
FY Total Cost by IC
2024
National Institute of Allergy and Infectious Diseases
$828,994
Year
Funding IC
FY Total Cost by IC
Sub Projects
No Sub Projects information available for 1R01AI178683-01A1
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 1R01AI178683-01A1
Patents
No Patents information available for 1R01AI178683-01A1
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 1R01AI178683-01A1
Clinical Studies
No Clinical Studies information available for 1R01AI178683-01A1
News and More
Related News Releases
No news release information available for 1R01AI178683-01A1
History
No Historical information available for 1R01AI178683-01A1
Similar Projects
No Similar Projects information available for 1R01AI178683-01A1